syndrome in Aboriginal and non-Aboriginal patients admitted to Western
Australian hospitals 2 
Background
Despite a reduction in the incidence of ischaemic heart disease (IHD) since the 1960s, acute coronary syndrome (ACS), the acute manifestation of IHD, contributes substantially to morbidity and mortality in Australia and internationally [1] [2] [3] . National statistics show that 75,000 Australians were hospitalised for ACS in 2010 alone, with death rates expected to increase by over 40% from repeat heart attack by 2020 2 .
Additionally, there are considerable disparities between Aboriginal and non-Aboriginal
Australians in the burden of IHD and other chronic conditions 4 5 . A reduction in these disparities can contribute significantly to the reduction in the gap in life expectancy between these populations.
Evidence suggests that adoption of a healthy life style and behavioural changes (diet, cessation of smoking and exercise), routine monitoring and addressing of health risk indicators (high blood pressure and cholesterol levels), dedicated cardiac rehabilitation programs, and the use of appropriate pharmacotherapy can significantly reduce mortality as well as morbidity following an ACS episode [6] [7] [8] [9] . Evidence-based consensus guidelines developed by the National Heart Foundation of Australia and Cardiac
Society of Australia and New Zealand for the management of ACS recommend prescription of four types of secondary prevention drugs: aspirin, statin, beta-blocker, and angiotensin-converting enzyme (ACE) inhibitor/Angiotensin II antagonist (ARB) example, data on the use of antiplatelet agents (e.g. aspirin), statins and beta-blockers from 11,543 patients in 14 countries indicated a significantly lower use in non-teaching hospitals compared to teaching hospitals 15 . A recent comparison study on ACS in the Northern Territory, Australia, documented significantly lower discharge prescription of statins among Aboriginal patients than non-Aboriginals 4 Although secondary preventive drug therapy has incrementally reduced the likelihood of ACS readmission and death 17 18 , questions have been raised about the suitability of such combinations of drugs in subgroups of ACS patients with chronic comorbidities 19 .
Comorbid conditions such as severe chronic obstructive pulmonary disease (COPD), and severe heart or kidney failure may be contraindications to the use of some of these secondary prevention drugs. Given the high burden of ACS in the general Australian population, the significant contribution of ACS to the gap in health between Aboriginal and non-Aboriginal Australians, and the potential of drug therapy to reduce recurrence and mortality, this study aimed to evaluate evidence based prescribing (EBP) of drugs at discharge from WA hospitals and to determine the predictors of evidence-based prescribing (EBP) for all ACS patients, as well as for Aboriginal and non-Aboriginal patients separately. The linked HMDC records allowed a series of continuous admissions for each patient (including transfers but without discharge home) to be grouped into episodes of care.
Methods

All
The current person-based analysis pertains to the last admission of the first episode in the study period in which ACS was a principal discharge diagnosis, for which we collected data and where the patient was discharged alive. These routinely collected administrative data were supplemented by clinical information pertaining to symptoms, medical history, drugs prescribed (inpatient and discharge) and procedures collected from medical notes in hospitals throughout WA and entered into a database.
Trained data collectors extracted information about the prescription of secondary prevention drugs for ACS during the admission and at discharge from medical notes, discharge summaries and drug charts. Demographic data including age, sex, ethnicity (Aboriginal: ever recorded as Aboriginal in HMDC or death record), residence (based on the Statistical Local Area in which address fell) and health insurance status were extracted from the hospital administrative records. Information on co-morbidities and risk factors such as smoking and hypertension wereas extracted from the medical history recorded in the written notes. Additionally, a 5-year history of admission for a range of co-morbidities was ascertained from the linked HMDC. Thus both physicianrecorded and administrative data were used to identify history of specific conditions, namely chronic kidney disease (CKD), heart failure (HF), chronic obstructive pulmonary diseases (COPD) including Asthma, Gastrointestinal (GI) bleeding and diabetes. Additionally, the Charlson comorbidity Index was calculated from the HMDC using a 5-year lookback period to provide a summary measure of general comorbidity 21 .
The primary outcome was prescription of at least 3 of the 4 evidence-based drugs for ACS at discharge. Evidence-based prescribing (EBP) was defined as prescription of aspirin plus a statin, as well as either a beta-blocker or ACE inhibitor/ARB. Where information on discharge drugs was missing but there was a record of having received ACS drugs during their hospital stay, it was assumed that they were prescribed at discharge. 
Ethics
Results
There was a total of 1717 patients included in the cohort and 499 (29%) were
Aboriginal (Table 1 ). Compared to non-Aboriginal patients (n=1218), Aboriginal patients were much younger (mean age 53 vs 65 years), more likely to be female (43% vs 30%) and living in a very remote area (27% vs 4.5%). A greater proportion of non-Aboriginal than Aboriginal patients were admitted for unstable angina (58% vs 48%), and were admitted to private hospitals (25% vs 6%). Aboriginal patients were twice as likely to be smokers and had two to three times higher prevalence of COPD, diabetes and CKD (Table1).
The overall characteristics of the groups that received EBP and the groups that had no ACS drugs recorded are also shown in Table 1 . Compared to the total groups, for both Aboriginal and non-Aboriginal patients, the EBP group had a higher proportion of patients who were discharged from metropolitan teaching hospitals, current smokers, patients with history of ACS, and hypertension, and a lower proportion of patients with heart failure and COPD. Compared with the total group, for both Aboriginal and nonAboriginal patients, those with no ACS drugs recorded were less likely to be discharged from a metropolitan teaching hospital (more likely to be a private hospital), have a history of hypertension and ACS, but were more likely to have smoking status not recorded.
The distribution of the possible combinations of ACS drugs and the overall prevalence for each drug and EBP are shown in Table 2 . Prescribing of secondary preventive drugs for ACS varied, with aspirin being the most common with about 90% of non-Aboriginal and 87% of Aboriginal patients receiving aspirin at discharge. Similar proportions of Aboriginal and non-Aboriginal patients had prescriptions for ACE inhibitor/ARB, while a significantly lower proportion of Aboriginal patients received beta-blockers.
Approximately three quarters of both Aboriginal and non-Aboriginal patients were prescribed statins at discharge.
Just over half (51%) of the patients received all four ACS drugs at discharge whilst 71%
had at least three of the four drugs prescribed, with similar proportions in Aboriginal and non-Aboriginal patients (Table 2) . However, a significantly higher proportion of
Aboriginal patients received none of the four drugs during their hospital stay or at discharge compared with non-Aboriginal patients (11% vs 7%; p<0.01). NonAboriginal patients were more likely than Aboriginal patients to have been prescribed a combination of aspirin, beta-blocker and statin at discharge ( Table 2) . Table 3 shows the unadjusted and adjusted odds ratios for each predictor of EBP in the combined groups of patients and Table 4 shows the adjusted odds ratios separately for
Aboriginal and non-Aboriginal patients. After adjusting for socio-demographic factors, hospital type and clinical comorbidities, the odds of EBP at discharge was 63% higher in men than women ( of ACS patients, respectively, were prescribed the four drug groups on discharge 22-24 .
Although secondary preventive drug therapy has incrementally reduced the likelihood of ACS readmission and death 17 18 , a significantly higher proportion of Aboriginal patients received none of the four drugs during their hospital stay or at discharge compared with non-Aboriginal patients (11% vs 7%; p<0.01) in this study. This finding has implications for 'closing the gap' between Aboriginal and non-Aboriginal population in Australia. Ensuring availability and continuation of ACS preventive drugs would contribute in increasing life expectancy and avoid deaths in Aboriginal patients.
While the rates of EBP in this study are comparable with reports from other cohorts, this study is more complete in its analysis of the predictors of EBP. The prescribing of any drug depends on contraindications, side effects and the patient's comorbid conditions. Although beta blockers may still be prescribed in patients with severe heart failure, COPD and asthma, they should be used with caution and close monitoring in patients with these comorbidities 27 . This may explain the slightly lower proportion of beta-blocker prescribing in Aboriginal patients in our study because they had a higher prevalence of heart failure and COPD than non-Aboriginal patients. Given the evidence that cardioselective beta blockers should not be withheld from patients with mild to moderate reactive airways disease or COPD 28 , our results suggest possible over-caution in this patient population.
Overall, comorbidities were independently associated with EBP in our study. Patients with a history of COPD were significantly less likely to receive these drugs than patients without COPD. In contrast, patients with diabetes and a history of ACS were more likely to have EBP at discharge than patients who were not diabetic or had no history of ACS. The reasons behind these variations are not straightforward. Reduced evidence-based therapies among patients with increased comorbidities have been reported in other studies [29] [30] [31] . Prescribing of discharge medications may also depend on the type of hospital and level of service providers involved in the management of ACS patients 15 22 32 .
Indeed, in our study we found that patients discharged from district hospitals were significantly less likely to have EBP at discharge than patients discharged from metro teaching hospitals. The association of EBP at discharge and type of hospital in our study may be partly attributed to the likelihood of cardiologists being involved in the care of patients with ACS at metro tertiary hospitals, but not at non-metro hospitals. There is evidence of a practice gap between cardiologists and general physicians found for the management of heart diseases in other studies 33 34 . Further, the significantly lower rate of EBP in district hospitals may be associated with the lack of trained health service providers, lack of awareness about national guidelines for ACS management and unavailability of long-term patient management plans at discharge. Compared to metroteaching hospitals, patients in private hospitals were also less likely to have EBP in our study, and this could be partly artefactual. The low level of EBP in private hospitals was also found in an Australian snapshot audit of ACS admissions in 2013 32 , reflecting an ongoing systemic issue in the private sector as well. Maintenance of hospital notes is another area that might have partly contributed to the lower rate of EBP not only in the district hospitals but also in private hospitals in this study.
The significantly lower rate of EBP among patients from regional and remote areas could be due to insufficient numbers of providers trained in the EBP for ACS management. In a multicentre study in Australia 35 , Interventions in these areas, including training of over 3000 hospital staff, resulted in a marked improvement in discharge prescribing of evidence-based ACS drugs, increasing from 57% preintervention to 69% post intervention. Further, the continuation of evidence based care relies on timely and legible communication of the discharge medication to primary care.
A limitation of our study is that we did not collect specific information on possible contraindications to the evidence-based drugs for each patient, so we could not assess definitively whether the lack of EBP was due to an absolute contraindication to the drug. However, from our linked data on hospital admissions we were able to identify comorbidities such as COPD that commonly lead to cautious prescribing of specific drugs.
In contrast, our study had a number of strengths. First, the state-wide collection of data from all hospitals in WA minimised selection bias in the study sample. Secondly, our data were reliable, having been extracted by trained data collectors (mostly nurses) from medical notes and drug charts in clinically confirmed cases of ACS. To ensure that there was no bias due to missing drug data, we included only patients who had at least one drug of any type recorded in their medication charts. In addition, if there were no data on discharge drugs prescribed, then we used inpatient drug data and assumed that evidence-based drugs used during the inpatient stay would have been continued at discharge. Overall, 4% to 8% of patients prescribed one of the 4 types of ACS preventive drugs during the hospital admission did not have them recorded in their discharge prescription. While the reasons for this were not elicited in the study, poor record keeping in some hospitals, particularly in rural and remote areas, could have accounted for some of this difference. Finally and most importantly, the use of linked data allowed tracking the full treatment history and journey of patients across all admissions, including transfers to other hospitals, and thus capturing the complete episode of ACS care.
Conclusions
The level of adherence to guidelines when prescribing drugs at discharge in our historical cohort of ACS patients in WA was found to be similar to results reported from more recent Australian cohorts. Moreover, no disparity in regards to the EBP of ACS preventive drugs has been observed between Aboriginal and non-Aboriginal patients'. However, as the overall level of EBP is only 70%, Therefore, there remains an opportunity to improve the level of prescribing of the guideline-recommended drugs at discharge from WA hospitals. Attention is particularly required for patients from rural and remote areas regarding pharmaceutical management post-ACS. The poor adherence to guidelines in district and private hospitals also needs further investigation, but may be an artefact due to suboptimal recording of treatment in the hospital notes. OR = Odds ratio, 95% CI = 95% confidence interval, MI = myocardial infarction, ACS = acute coronary syndrome, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease.
